Review
New antiplatelet agents for cardiovascular disease
Doson Chua and Cesilia Nishi
CMAJ November 05, 2013 185 (16) 1405-1411; DOI: https://doi.org/10.1503/cmaj.130033
Doson Chua
Department of Pharmacy, St. Paul’s Hospital, Vancouver, BC
PharmDCesilia Nishi
Department of Pharmacy, St. Paul’s Hospital, Vancouver, BC
PharmD![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Related Articles
- (2013). Highlights. CMAJ, 185(16), 1375. Accessed August 15, 2024. Retrieved from http://www.cmaj.ca/content/185/16/1375.
In this issue
Article tools
Respond to this article
New antiplatelet agents for cardiovascular disease
Doson Chua, Cesilia Nishi
CMAJ Nov 2013, 185 (16) 1405-1411; DOI: 10.1503/cmaj.130033
Jump to section
- Article
- What is the current standard for antiplatelet therapy after acute coronary syndromes?
- How do the new antiplatelet agents differ from clopidogrel?
- What is the evidence for the new antiplatelet agents in acute coronary syndromes?
- What are the harms of the new antiplatelet agents?
- How are these new agents used with oral anticoagulants?
- What are other considerations in the use of these new agents?
- Gaps in knowledge
- Footnotes
- References
- Figures & Tables
- Responses
- Metrics